Co-LEsions in Alzheimer Disease and Related Disorders

NCT02052947 | Unknown

• 1 other identifier: 2013.795
• Study Type: interventional
• Target: 214
• Locations: 1 country
• Sites: 1

Brief Summary

One of the crucial challenges for the future of Alzheimer's disease (AD) therapeutic approaches in elderly is to target the main pathological process responsible for disability and dependency. However, a progressive cognitive impairment occurring after the age of 70 is often related to mixed lesions of neurodegenerative and vascular origins. Whereas young patients are mostly affected by pure lesions, aging favors the occurrence of co-lesions of AD, vascular and Lewy body types. Pure DLB (Dementia with Lewy Body) and AD are distinct disorders but they often coexist in old age patients, the Abeta pathology of DLB/AD cases being different to that observed in patients with AD alone. Vascular dementia (VD) and AD with cerebrovascular disease (AD+CVD) are the leading causes of dementia next to AD alone. Lack of consensus persists about the diagnosis criteria for VD and AD+CVD, due in part to their clinical, pathological heterogeneity and the multiple pathological subtypes. We do not know the precise role and weight of each brain lesion type in the disability progression in elderly. To target the actual pathological process, we need to disclose the functional weight of AD, Lewy body and vascular lesion types in elderly. Most of the studies report on functional and clinical abnormalities in patients with pure pathologies. Thus, co-morbid processes involved in the transition from an independent functional status to disability in the elderly with co-lesions still remain to be elucidated. Neuropathological examination often performed at late stages cannot answer this question at mild or moderate stages. Brain MRI, Single Photon Emission Computed Tomography (SPECT) with DaTscan® and CSF biomarkers help routinely in performing the diagnosis of pure or mixed lesions responsible for dementia. The topography of the atrophy in MRI helps to provide information about the etiological diagnosis. Medial temporal lobe atrophy on MRI has good discriminatory power for AD compared to DLB and VD in pathologically confirmed cases. DaTscan® SPECT presents with good sensitivity and specificity at early stages of DLB. The good diagnosis value of CSF biological markers has led recently to their inclusion in the research diagnosis criteria of AD. Low Aβ1-42 and high levels of total tau and hyperphosphorylated tau isoforms appear to be the most sensitive and specific CSF biomarkers. Aβ1-42 is lowered in AD, as well as in other neurodegenerative diseases like DLB, VD. The combination of MRI, particularly medial temporal atrophy measures and vascular lesions on FLAIR MRI sequences, SPECT and CSF biomarkers seem to be of incremental value for the diagnosis AD, VD, DLB and mixed profiles. The aim of this study is to identify the biomarkers (MRI, SPECT-DaTscan® and CSF), and their combination, that are the most predictive of functional disability in elderly presenting with a progressive cognitive decline related to AD, DLB, VD and all mixed patterns.

Conditions

Alzheimer's Disease; Cerebrovascular Disease; Lewy Body Disease

Keywords

Alzheimer's disease; cerebrovascular disease; Lewy body disease; MRI; SPECT; CSF; biomarkers; disability; Multicenter and prospective cohort study

Outcome Measures

Primary Outcomes (1)

• Disability progression

  defined by the Disability Assessment in Dementia (DAD) scale (Gauthier, Gelinas et al. 1997; Gelinas, Gauthier et al. 1999)

  2 years

Secondary Outcomes (3)

• Neuropsychological inventory

  2 years

• NeuroPsychiatric inventory

  2 years

• Clinical/serum markers

  2 years

Study Arms (1)

SPEC-DaTscan

OTHER

SPEC-DaTscan

Radiation: SPECT-DaTscan

Interventions

SPECT-DaTscan RADIATION

* Measurement of fixation of DaTscan® in the caudate and lenticular nucleus * LP (Lumbar Puncture): the LP will follow the last guidelines published in 2011 (Armand Perret-Liaudet is co-author of these guidelines; Perret-Liaudet A. et al, Cerebrospinal Fluid Collection Tubes: a critical issue for Alzheimer Disease diagnosis. Clin Chem, 2012, accepted).

SPEC-DaTscan

Eligibility Criteria

• Age: 70 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)

You may qualify if:

• Male or female subject aged over 70 years
• Out-patient consulting at one of the Memory Centres participating to the study
• Patients meeting diagnosis criteria for dementia due to Alzheimer's disease (McKhann, Knopman et al. 2011), vascular dementia (NINCDS-AIREN criteria, Roma´n, G. C., Tatemichi, T. K., Erkinjuntti, T., et al. (1993), Lewy body disease (McKeith, Dickson et al. 2005), and patients presenting with mixed signs and symptoms suggesting a combination of these diagnosis
• Mild or moderate dementia stage (MMSE criteria \> 15)
• Being affiliated to health insurance
• Patient with sufficient visual, auditory and oral and written French language skills to complete the clinical and neuropsychological evaluations
• Accompanied by a close relation in sufficient contact with the subject to assess their dependency

You may not qualify if:

• Patients with psychiatric disorders (Axe 1 DSMIV (Diagnostic and Statistical Manual of Mental Disorders) disease) excepted patients with depressive or anxious disorders stabilized for more than 3 months
• Patients taking any neuroleptic psychotropic medication
• Patients taking other psychotropic medication, with the exception of any antidepressant, hypnotic, anxiolytic, acetylcholinesterase inhibitors or memantine which has been prescribed and stabilised for more than 3 months
• Patients with signs and symptoms suggestive of dementia related to other diseases than AD, vascular and Lewy diseases, or mixed forms
• Patients with other neurological diseases
• Patients with progressive and unstable pathologies which could interfere with the variables under consideration
• Deafness or blindness which could compromise evaluation of the patient
• Patients being not able to undergo DaTscan®: with moderate or severe hepatic or renal impairment, a known hypersensitivity to ioflupane or any of the excipients
• Patient living in an institution
• Patient being under guardianship

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (1)

Hopital Charpennes

Villeurbanne, 69100, France

RECRUITING

Related Publications (1)

• Boublay N, Federico D, Pesce A, Verny M, Blanc F, Paccalin M, Desmidt T, Grosmaitre P, Moreaud O, Relland S, Bravant E, Bouet R, Krolak-Salmon P. Study protocol on Alzheimer's disease and related disorders: focus on clinical and imaging predictive markers in co-existing lesions. BMC Geriatr. 2018 Nov 14;18(1):280. doi: 10.1186/s12877-018-0949-2.

  PMID: 30428832 DERIVED

MeSH Terms

Conditions

Alzheimer Disease; Cerebrovascular Disorders; Lewy Body Disease

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders; Vascular Diseases; Cardiovascular Diseases; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies

Central Study Contacts

Nawele Boublay

CONTACT

0472856302; nawele.boublay@chu-lyon.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SCREENING
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 16, 2014
• First Posted: February 3, 2014
• Study Start: January 1, 2014
• Primary Completion: July 1, 2018
• Study Completion: October 1, 2020
• Last Updated: August 23, 2017

Record last verified: 2017-08

Locations

FR (1)